---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-168096"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:35:40.617391+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Larimar Therapeutics reports preliminary cash balance of $138.5M as of June 30, 2025

## Summary
- Preliminary unaudited cash, cash equivalents and marketable securities of $138.5M as of June 30, 2025.
- Disclosed in a preliminary prospectus supplement filed under Rule 424(b)(5) on July 29, 2025.
- Financial close for Q2 2025 not complete; amount subject to change.

## SEC filing metadata
- accession: 0001193125-25-168096
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000119312525168096/0001193125-25-168096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000119312525168096/d927864d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-168096
- JSON: https://secwatch.observer/filing/0001193125-25-168096.json
- Plain text: https://secwatch.observer/filing/0001193125-25-168096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.